Anoctamin-1 Expression Positive
Anoctamin-1 Expression Positive serves as an inclusion eligibility criterion in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain Anoctamin-1 Expression Positive as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open).
Trials with Anoctamin-1 Expression Positive in the inclusion eligibility criteria most commonly target gastrointestinal stromal tumor .
Imatinib and spartalizumab are the most frequent therapies in trials with Anoctamin-1 Expression Positive as an inclusion criteria .
Significance of Anoctamin-1 Expression Positive in Diseases
Gastrointestinal Stromal Tumor +
Anoctamin-1 Expression Positive is an inclusion criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 3 are open and 0 are closed. Of the trials that contain Anoctamin-1 Expression Positive and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) .
Imatinib and spartalizumab are the most frequent therapies in trials for gastrointestinal stromal tumor that contain Anoctamin-1 Expression Positive .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.